Prescription proton pump inhibitors may cause hypomagnesemia if taken for prolonged periods of time (in most cases longer than 1 year), according to FDA.
Prescription proton pump inhibitors (PPIs) may cause hypomagnesemia if taken for prolonged periods of time (in most cases longer than 1 year), according to FDA. FDA noted that in one-quarter of cases reviewed from the Adverse Event Reporting System, medical literature and periodic safety update reports, magnesium supplementation alone did not improve low magnesium levels, necessitating the discontinuation of PPIs.
Adverse events attributed to low magnesium levels include tetany, arrhythmias, and seizures. Hypomagnesemia may also cause impaired parathyroid secretion leading to hypocalcemia. Treatment of hypomagnesemia generally requires magnesium supplements and possible discontinuation of the PPI.
FDA recommends that healthcare professionals consider obtaining serum magnesium levels prior to the initiation of PPI therapy from those patients who they anticipate will be on a long course of therapy, as well as from those taking digoxin, diuretics, or drugs that may cause hypomagnesemia. This is especially important for patients taking digoxin because low magnesium can increase the likelihood of serious side effects; therefore, obtaining magnesium levels periodically in these patients is recommended.
Patients taking both loop diuretics (furosemide, bumetanide, torsemide, and ethacrynic acid) and thiazide diruretics (chlorothiazide, hydrochlorothiazide, indapamide, and metolazone) may be at risk for hypomagnesemia. Hypomagnesemia may occur when these agents are used alone or when combined with other antihypertensives such as beta-blockers, angiotensin receptor blockers, and/or ACE inhibitors.
In contrast, over-the-counter (OTC) PPIs contain low doses and are intended only for a 14-day course of treatment up to 3 times per year. FDA reports there is very little risk of hypomagnesemia when patients use OTC PPIs per the instructions on the label. However, because patients may take OTC PPIs for periods that exceed the directions on the OTC label, either on their own initiative or based on a healthcare professional's recommendation, FDA advises healthcare professionals to communicate the risk of hypomagnesemia to them.
FDA will add to the WARNINGS AND PRECAUTIONS sections of the labels for all the prescription PPIs information about the potential risk of hypomagnesemia.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More